MarketCap
Facebook
X
Telegram
Biodesix General and Administrative Expenses | BDSX
General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.What these expenses include
- Salaries of administrative staff (executives, HR, accountants, legal personnel)
- Office rent and utilities
- Office equipment and IT infrastructure
- Professional services (auditors, lawyers, consultants)
- Insurance
- General administrative travel and representation expenses
- Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure - Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit - Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry - Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines
Annual General and Administrative Expenses Biodesix
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 87.5 M | 80.5 M | 67.4 M | 61.5 M | 50.5 M | 34.9 M | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 87.5 M | 34.9 M | 63.7 M |
Quarterly General and Administrative Expenses Biodesix
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 24.3 M | 24.3 M | 21.7 M | 22.4 M | 20.4 M | - | 20 M | 19.7 M | 20.6 M | - | 15.5 M | 16.7 M | 19 M | - | 15.1 M | 15.2 M | 14.5 M | - | 13.6 M | 11.4 M | 11.9 M | - | 7.88 M | 6.83 M | 8.08 M | - | 8.21 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 24.3 M | 6.83 M | 16.1 M |
General and Administrative Expenses of other stocks in the Diagnostics research industry
| Issuer | General and Administrative Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Aspira Women's Health
AWH
|
7.96 M | - | -6.19 % | $ 10.5 M |  USA |
 |
Check-Cap Ltd.
CHEK
|
2.37 M | - | - | $ 9.42 M |  Israel |
 |
Exact Sciences Corporation
EXAS
|
889 M | - | - | $ 19.8 B | USA |
 |
Interpace Biosciences
IDXG
|
9.48 M | $ 1.45 | 2.11 % | $ 6.41 M | USA |
 |
Organovo Holdings
ONVO
|
7.43 M | - | -2.3 % | $ 19.4 M | USA |
 |
OpGen
OPGN
|
3.13 M | - | -16.95 % | $ 1.54 M | USA |
 |
PerkinElmer
PKI
|
992 M | - | -0.91 % | $ 14.7 B | USA |
 |
Soleno Therapeutics
SLNO
|
132 M | - | - | $ 2.69 B | USA |
 |
Enzo Biochem
ENZ
|
21.7 M | - | -8.98 % | $ 14.8 K | USA |
 |
Agilent Technologies
A
|
1.71 B | $ 171.29 | 2.09 % | $ 48.6 B | USA |
 |
Anixa Biosciences
ANIX
|
6.63 M | $ 2.95 | 6.5 % | $ 95.7 K | USA |
 |
Biomerica
BMRA
|
3.23 M | $ 2.05 | 0.84 % | $ 5.98 M | USA |
 |
BioNano Genomics
BNGO
|
35.2 M | $ 1.45 | 0.96 % | $ 7.9 M | USA |
 |
Burning Rock Biotech Limited
BNR
|
126 M | $ 15.83 | 0.62 % | $ 166 M |  China |
 |
Bioventus
BVS
|
314 M | $ 13.52 | 2.97 % | $ 901 M | USA |
 |
CareDx, Inc
CDNA
|
108 M | $ 69.85 | 4.02 % | $ 3.72 B | USA |
 |
Celcuity
CELC
|
27.2 M | $ 73.62 | 2.11 % | $ 3.44 B | USA |
 |
Co-Diagnostics
CODX
|
9.06 M | $ 1.1 | 1.85 % | $ 1.46 M | USA |
 |
Charles River Laboratories International
CRL
|
743 M | $ 310.77 | 7.07 % | $ 15.4 B | USA |
 |
Castle Biosciences
CSTL
|
229 M | $ 36.65 | 3.07 % | $ 1.06 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
1.97 B | $ 232.22 | 0.07 % | $ 25.8 B | USA |
 |
Danaher Corporation
DHR
|
8.24 B | $ 221.21 | 3.34 % | $ 158 B | USA |
 |
DarioHealth Corp.
DRIO
|
15.2 M | $ 5.8 | 1.24 % | $ 23.1 M | Israel |
 |
DexCom
DXCM
|
1.29 B | $ 86.9 | 1.8 % | $ 33.9 B | USA |
 |
Fulgent Genetics
FLGT
|
117 M | $ 22.45 | 4.52 % | $ 691 M | USA |
 |
Guardant Health
GH
|
211 M | $ 187.22 | 5.3 % | $ 23.5 B | USA |
 |
ICON Public Limited Company
ICLR
|
780 M | $ 168.33 | 3.88 % | $ 13.2 B |  Irlanda |
 |
IDEXX Laboratories
IDXX
|
405 M | $ 527.07 | 1.67 % | $ 42.4 B | USA |
 |
Illumina
ILMN
|
1.09 B | $ 293.69 | 7.56 % | $ 45.5 B | USA |
 |
IQVIA Holdings
IQV
|
2 B | $ 266.09 | 3.05 % | $ 45.7 B | USA |
 |
Laboratory Corporation of America Holdings
LH
|
2.22 B | $ 308.65 | 0.05 % | $ 25.7 B | USA |
 |
Lantheus Holdings
LNTH
|
275 M | $ 100.19 | 0.23 % | $ 6.76 B | USA |
 |
Medpace Holdings
MEDP
|
198 M | $ 620.51 | 3.51 % | $ 17.9 B | USA |
 |
Mettler-Toledo International
MTD
|
998 M | $ 1 541.63 | 3.73 % | $ 31.8 B |  Schweiz |
 |
Myriad Genetics
MYGN
|
257 M | $ 4.58 | 0.88 % | $ 424 M | USA |
 |
ENDRA Life Sciences
NDRA
|
3.72 M | $ 6.31 | 4.13 % | $ 4.97 M | USA |
 |
NeoGenomics
NEO
|
273 M | $ 19.13 | 3.57 % | $ 2.45 B | USA |
 |
Neogen Corporation
NEOG
|
245 M | $ 13.01 | 7.08 % | $ 2.83 B | USA |
 |
National Research Corporation
NRC
|
54.8 M | $ 20.78 | 2.11 % | $ 465 M | USA |
 |
Natera
NTRA
|
1.18 B | $ 425.64 | 3.73 % | $ 58.2 B | USA |
 |
OPKO Health
OPK
|
223 M | $ 1.57 | 0.64 % | $ 1.18 B | USA |
 |
Pacific Biosciences of California
PACB
|
141 M | $ 2.87 | 12.99 % | $ 861 M | USA |
 |
Koninklijke Philips N.V.
PHG
|
628 M | $ 23.91 | 0.04 % | $ 22.7 B |  Niderland |
 |
Precipio
PRPO
|
9.45 M | $ 24.0 | 3.76 % | $ 38.5 M | USA |
 |
Personalis
PSNL
|
53.6 M | $ 16.4 | 0.74 % | $ 1.46 B | USA |
 |
Quidel Corporation
QDEL
|
66.6 M | $ 12.14 | 12.72 % | $ 511 M | USA |
 |
QIAGEN N.V.
QGEN
|
128 M | $ 45.79 | 2.34 % | $ 9.95 B | Niderland |
 |
RadNet
RDNT
|
1.82 M | $ 70.63 | 1.0 % | $ 5.31 B | USA |
 |
Senseonics Holdings
SENS
|
52.5 M | $ 10.31 | 4.35 % | $ 430 M | USA |